Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Perrigo OTC nicotine mint-flavored mini lozenge ANDA
The OTC smoking cessation lozenge, which is mint flavored, is available in different doses including 2 mg and 4 mg. The product is indicated to reduce withdrawal symptoms,
The OTC smoking cessation lozenge, which is mint flavored, is available in different doses including 2 mg and 4 mg. The product is indicated to reduce withdrawal symptoms,
Under the agreement, Iverson gained marketing rights for the product which determines the healthy cholesterol fraction, HDL, and its partner protein, scavenger receptor class B type I (SR-BI).
The proposed plant will be built on Novasep’s existing Mourenx site in France and is expected to be operational and validated within 18 months. The new plant will include
The 4,900m² factory will manufacture medicinal packages for infections, cardiovascular issues, hypertension, respiratory issues, oncology and diabetics. MSD Asia Pacific president Patrick Bergstedt was quoted by The Jakarta
The approval as the distributor follows ScripsAmerica’s completion of a screening process requiring multiple business references and the ability to provide quality of pharmaceutical distribution services. ScripsAmerica CEO
The Phase 2b/3a trial, designed to assess the safety and efficacy of amitifadine, has randomised a total of 342 MDD patients at 39 centres in the US. Euthymics
Strike Axe president Shaun Sullivan said Wayne will navigate the current economic conditions as a small business entrepreneur and will help in shaping the direction of Strike Axe.
The new technology with thin and clear co-extruded film will provide an extra layer of product security for pharmaceutical brands. Sharp Tear has been designed for tamper-evident applications,
The patents protect compositions and processes for making spray-dried dispersions (SDDs) made with an active pharmaceutical ingredient and hydroxypropyl methylcellulose acetate succinate (HPMCAS), a polymer also known as
The grant will advance the development to further characterize a potent inhibitor of glycolysis targeting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in models of Glioblastoma Multiforme (GBM). ACT president and CEO